AU6535594A - A method of detecting the presence of and converting of a polypeptide - Google Patents
A method of detecting the presence of and converting of a polypeptideInfo
- Publication number
- AU6535594A AU6535594A AU65355/94A AU6535594A AU6535594A AU 6535594 A AU6535594 A AU 6535594A AU 65355/94 A AU65355/94 A AU 65355/94A AU 6535594 A AU6535594 A AU 6535594A AU 6535594 A AU6535594 A AU 6535594A
- Authority
- AU
- Australia
- Prior art keywords
- growth hormone
- hgh
- rhgh
- hydrophobic
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 title description 15
- 102000004196 processed proteins & peptides Human genes 0.000 title description 7
- 229920001184 polypeptide Polymers 0.000 title description 3
- 239000000854 Human Growth Hormone Substances 0.000 claims description 66
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 66
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 66
- 239000000122 growth hormone Substances 0.000 claims description 47
- 102000018997 Growth Hormone Human genes 0.000 claims description 46
- 108010051696 Growth Hormone Proteins 0.000 claims description 46
- 230000002209 hydrophobic effect Effects 0.000 claims description 34
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 22
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 18
- 235000018417 cysteine Nutrition 0.000 claims description 16
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 15
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 9
- -1 mercapto compound Chemical class 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000012634 fragment Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 206010062767 Hypophysitis Diseases 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 210000003635 pituitary gland Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003111 growth hormone derivative Substances 0.000 description 3
- 229940121366 growth hormone derivative Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000012510 peptide mapping method Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
- 206010027146 Melanoderma Diseases 0.000 description 2
- 108010013127 Met-human growth hormone Proteins 0.000 description 2
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940046892 lead acetate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000013385 tryptic peptide mapping Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 101000731000 Homo sapiens Membrane-associated progesterone receptor component 1 Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102100032399 Membrane-associated progesterone receptor component 1 Human genes 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000002607 Pseudarthrosis Diseases 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- XCAUINMIESBTBL-UHFFFAOYSA-N lead(ii) sulfide Chemical compound [Pb]=S XCAUINMIESBTBL-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009576 somatic growth Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
TITLE
A method of detecting the presence of and converting of a polypeptide.
FIELD OF THE INVENTION
The present invention relates to a method of detecting the presence of a hydrophobic derivative of a growth hormone and a method for converting the derivative into the native form of the growth hormone.
BACKGROUND OF THE INVENTION
The growth hormones from man and from the common domestic animals are proteins of approximately 191 amino acids, syn¬ thesized and secreted from the anterior lope of the pituitary gland. Human growth hormone consists of 191 amino acids having a molecular weight of 22125 D. Four cystein residues are present giving rise to two disulfide bridges. The disulfide bridge formed between Cys(53) and Cys(165) results in a major loop, and the disulfide bridge between Cys(182) and Cys(189) results in a minor loop.
Growth hormone is a key hormone involved in the regulation of not only somatic growth, but also in the regulation of meta¬ bolism of proteins, carbohydrates and lipids.
The organ systems affected by growth hormone include the ske¬ leton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys.
Until the development of the recombinant technology and the cloning of the growth hormone gene now giving rise to produc¬ tion of e.g. human growth hormone (hGH) and Met-hGH in indu¬ strial scale, human growth hormone could only be obtained by extraction from the pituitary glands of human cadavers.
The very limited supplies of growth hormone restricted the use thereof to longitudinal growth promotion in childhood and puberty for treatment of dwarfism, even though it has been proposed for inter alia treatment of short stature (due to growth hormone deficiency, normal short stature and Turner syndrom) , growth hormone deficiency in adults, infertility, treatment of burns, wound healing, dystrophy, bone knitting, osteoporosis, diffuse gastric bleeding, and pseudoarthrosis.
Furthermore, growth hormone has been proposed for increasing the rate of growth of domestic animals, for decreasing the proportion of fat in animals to be slaughtered for human con¬ sumption, and for increasing the production of milk in lactating animals.
In recombinant technigues human growth hormone is normally produced by expressing a gene coding for human growth hormon, said gene being inserted into a microorganism. The growth hormone is then isolated from the broth, optionally after lysing the microorganisms. The host most commonly used for expressing hGH is E. coli.
Growth hormone extracted from pituitary glands or growth hormone produced by recombinant techniques is always compared with suitable standards in order to ensure the identity with an authentic product.
hGH extracted from pituitaries have been investigated in order to detect aberrant forms and determine their specific activities. Besides the growth hormone with a molecular weight as mentioned above a variant single chain form is also produced, wherein the amino acid residues 32-46 are omitted resulting in the socalled 20k form of hGH. This variant is the result of alternate splicing at the m- NA level. Also variants related to mass, charge, rearrangements, oxidized forms, and split forms are described to be present in hGH- preparations isolated from pituitary glands.
The development of new assays has enabled detection of derivatives of growth hormone present in very small amounts in preparations and standards. Thus, a hitherto unknown hydrophobic impurity has been detected in connection with the purification of human growth hormone preparations using Hydrophobic Interaction Chromatography (HIC) under special conditions. This derivative is normally not detected by any of the other methods employed for testing a sample of human growth hormone including SDS-PAGE, RP-HPLC, IE-HPLC and GPC or by the HIC method run under other conditions.
For preparing pharmaceutical preparations it is generally preferred to employ active ingredients in a form as pure as possible and, if possible, it is preferred to employ active ingredients being monocomponent compounds.
It is desirable to find a method for easy detection of the presence of the hydrophobic derivative of growth hormone disclosed herein as well as a need for a method for removing the derivatives from a batch of growth hormone.
It is also possible to remove the hydrophobic derivative by physical separation techniques. However, such a procedure alone is less desirable due to loss of active ingredient.
Thus there is also a need for a process which will ensure a quantitative conversion of the hydrophobic derivative of growth hormone directly into the native product.
BRIEF DESCRIPTION OF THE INVENTION
It has now been found that the hydrophobic derivative of hu¬ man growth hormone disclosed herein may easily be detected by chro atographic methods and may easily be converted into the native form of human growth hormone.
Thus, in a first aspect, the invention relates to a method for detection of the presence of a hydrophobic derivative of a growth hormone comprising an extra sulphur atom as compared to the native growth hormone wherein the growth hormone is subjected to a hydrophobic interaction chromatography eluting the column using a gradient of ammonium sulphate and detecting the presence of the hydrophobic derivative.
Hydrophobic interaction chromatography is inter alia described in LC&GC.INTL Vol. 5, No. 11 (1992) 24-29.
The HIC may be carried out using a column of phenyl superose in a FPLC apparatus. A convenient apparatus is the FPLC apparatus Phenyl Superose HR 5/5 offered by Pharmacia.
The elution may be carried out using suitable salts such as ammonium sulphates and/or ammonium acetate.
The fractions of the eluate from the HIC comprising the hydrophobic derivative of growth hormone may then be subjected to peptide mapping as disclosed in Chapter 9 in High Performance Liquid Chromatography in Biotechnology, Edited by William S. Hancock, Published by John Wiley & Sons, Inc, 1990.
The hydrophobic derivative of growth hormone may be detected by comparing retention times as the fragment comprising a trisulphide bridge has a longer retention time as compared to the corresponding fragment comprising disulphide bridge.
In a further aspect, the present invention relates to a method for converting a hydrophobic derivative of a growth hormone into the native form of the growth hormone.
It has surprisingly been found that the hydrophobic derivati¬ ve of human growth hormone may be converted into the native form thereof by treating the derivative with a mercapto
compound. The treatment is conveniently carried out in a solution comprising the hydrophobic derivative of human growth hormone in a solvent.
It has also been found that such hydrophobic derivatives may be converted directly into the native form by a gentle treatment using a mercapto compound. Thus, the conversion or "refolding" may according to the invention be carried out using a conventional buffer for refolding of proteins, but without the preceding reduction or denaturation to break the disulfide bridges normally relied upon when refolding proteins.
According to a still further aspect of the invention the hydrophobic derivative of hGH is isolated before carrying out the convertion into native hGH.
It is preferred to treat the whole batch of growth hormone comprising the hydrophobic derivative of hGH directly without isolating the growth hormone derivative.
The mercapto compound may be any mercapto compound not having an adverse effect on the growth hormone under the reaction conditions. Preferred compounds are such compounds which are able to transform the growth hormone derivative directly into the native form without having to reduce the growth hormone totally breaking both sulphur bridges present in native growth hormone. The mercapto compound may e.g. be cysteine, glutathione, 2-mercapto ethanol or dithiothreitol (DTT) .
Preferred compounds are selected from the group consisting of cysteine and glutathione. Most preferred is cysteine.
The mercapto compound is normally present in the solution in a concentration of from 0.1 and up to 5 mM. Preferably the concentration is in the interval from 0.5 to 3 mM. According to a preferred aspect of the invention, the growth hormone is treated with cysteine in a concentration of 1 to 2 mM.
In the present context "growth hormone" may be growth hormone from any origin such as avian, bovine, equine, human, ovine, porcine, salmon, trout or tuna growth hormone, preferably bovine, human or porcine growth hormone, human growth hormone being most preferred. The growth hormone to be treated in accordance with the present invention may be growth hormone isolated from a natural source, e.g. by extracting pituitary glands in a conventional manner, or a growth hormone produced by recombinant techniques, e.g as described in E.B. Jensen and S. Carlsen in Biotech and Bioeng. 3_6, 1-11 (1990). The preferred growth hormone is hGH.
The "growth hormone" may also be a truncated form of growth hormone wherein one or more amino acid residues has (have) been deleted; an analogue thereof wherein one or more amino acid residues in the native molecule has (have) been substi¬ tuted by another amino acid residue, preferably a natural amino acid residue, as long as the substitution does not have any adverse effect such as antigenicity or reduced action; or a derivative thereof, e.g having an N- or C-terminal exten- sion such as Met-hGH, Met-Lys-hGH, Ala-Glu-hGH, Thr-Glu-Ala- Glu-hGH, Ala-Glu-Ala-Glu-hGH, Met-Glu-Ala-Glu-hGH, Met-Phe- Glu-Glu-hGH, Met-Asp-Ala-Asp-hGH, or Met-Glu-Ala-Asp-hGH.
The solvents used to prepare the solution of derivative of the growth hormone to be treated may e.g. be an aquous buffer buffered at a pH from 5 to 10. Solutions being buffered to a pH > 6 are preferred. The solvent is preferably selected from the group consisting of Tris, triethylamine, citric acid, phosphate buffer, and histidine, Tris being the preferred buffer.
A preferred buffered solution is buffered to pH 7.5 using 20 mM Tris and 10 mM citric acid.
DETAILED DESCRIPTION OF THE INVENTION
The identity of amino acid sequence of the hydrophobic variant of human growth hormone with that of human growth hormone has been determined by tryptic peptide mapping, amino acid sequence analysis of isolated peptide fragments. Furthermore, mass spectrometry has been carried out.
The mass spectrometry showed an increase of mass of 32 dal- tons of the hydrophobic derivative of hGH as compared to na¬ tive hGH. This can be assigned to the presence of an extra sulphur atom.
From the results of the characterization of the hydrophobic growth hormone derivative it was concluded that the derivati¬ ve is a human growth hormone having one disulphide bridge (Cys 53-Cys 165) and one trisulphide bridge (Cys 182 - S - Cys 189) and having an amino acid sequence identical to that of native hGH.
EXPERIMENTAL PART
Example 1
Detection of Hydrophobic Derivative of Human Growth Hormone.
The presence of a hydrophobic derivative of recombinant human growth hormone comprising an extra sulphur atom as compared to the native form thereof was detected in accordance with the invention by subjecting the growth hormone to HIC using a FPLC apparatus (Pharmacia) and column of Phenyl Superose HR 5/5 from Pharmacia.
For elution a gradient of ammonium sulphate is used.
The buffer system was:
Buffer A: 1.2M ammonium sulphate, 20mM Tris pH 7.4 Buffer B: 20mM Tris pH 7.4
The chemicals used were all Merck p.a.
5 The elution was carried out using the following gradient:
Time (min.) Buffer
0.0 Cone %B 0.0
1.0 Cone %B 0.0
10.0 Cone %B 100
10 16.0 Cone %B 100
17.0 Cone %B 0
22.0 End
The buffer was added at a rate of 0.50 ml /min, and the feed rate of the paper was 0.50 cm/min.
15 The fractions of the eluate comprising the hydrophobic derivative were subjected to peptide mapping as described above.
Alternative Mehod of Detection of Hydrophobic Derivative of Human Growth Hormone
20 hGH samples were analyzed on a TSK Ether 5PW (75 x 4.6 mm ID) column at ambient temperature using eluent C and D and a gradient from 40 to 50% eluent D during 30 minutes. Eluent ,C: 2 M (NH4)2SOA, 20 mM Na2HP04 x 2H20, pH 6.0. Eluent D: 20 mM Na2HP04 x 2H20, 0.1% PEG, pH 6.0. Detection was performed at
25280 nm. Flow: 0.5 ml/min. HPLC equipment: Data handling and control: Waters 860 Networking computer system, Pumps: Waters
pumps model 510, Sample injectors: Waters Wisp 712, Detector: Waters M481 spectrophotometer.
The hydrophobic derivative of recombinant human growth hormone (rhGH') was identified by the appearance of an new peak between peak 8 and peak 9 coupled with the disappearance of peak 7 (the 7 peptide) corresponding to amino acid residues 179-191 in a peptide mapping of recombinant human growth hormone (rhGH) . The numbering of the peaks are as disclosed in Chapter 9 in High Performence Liquid Chromatographi (Supra) .
Isolation of hydrophobic Derivative of Human Growth Hormone
If it is desired to isolate the hydrophobic derivative from a sample of hGH, such isolation may be carried out by scaling up the procedure described above, or such isolation may e.g. be carried out using the method as described in Bio/Technology 5 (1987) 161-164.
Characterization of Hydrophobic Derivative of Human Growth Hormone by Mass Speetroscopy
Recombinant human growth hormone was analyzed by Plasma Desorption Mass Speetroscopy (PDMS) and Electro-Spray Mass Speetroscopy (ESMS) , respectively.
The analysis focused on the detecting the difference between the intact rhGH and rhGH' and the corresponding 7 and 7' tryptic peptides, respectively.
Determination of Mass of Intact rhGH and rhGH'
The mass of intact rhGH and rhGH1 was analyzed by ESMS performed using a API III LC/MS/MS system (Sciex. Thornhill, Ontario, Canada) . The triple quadropople instrument had a
mass-to-charge (m/Z) range of 2400 and was fitted with a pneumatically assisted electrospray (also referred to as ion- spray) interface (PI, PI) . Sample introduction was done by a syringe infusion pump (Sage Instruments, Cambridge, MA) 5 thorugh a fused capillary (75 μm i.d.) with a liquid flow rate set at 0.5-1 μl/min. The instrument m/z scale was calibrated with single charged ammonium adduct ions of poly(propylene glycols) (PPG's) under unit resolution. The accuracy of mass determination was in generally better than 100.02%, but low intensity spectra may result in less precise mass determination.
Plasma Desorption Mass Spectometry (PDMS) analysis was performed using a BIO-ION 20K 252-Californian time-of-flight instrument (ABI Nordic A/S, Uppsala, Sweden). Standard 15 procedures for sample application (including in situ reduction using DTT) and analysis were followed (P3,P4). The accuracy of Mass determination was about 0.1%.
Before the analysis, both rhGH and rhGH' were desalted on a Sep-pak (Stationary phase C18 from Waters) . The rhGH' showed 20 an increase of mass of 31±2 amu as compared with rhGH. After reduction using DTT, the mass of the rhGH* is identical to the calculated mass for reduced hGH.
The results are shown in the below Table I.
Table I
ESMS Calculated
25 rhGH 22126±2 22125.2 rhGH' 22157±2 rhGH' + DTT 22129±2
Determination of Mass of the tryptic fragment No. 7 of rhGH and rhGH'
The mass of the tryptic fragment No. 7 of rhGH and rhGH', the 7 and 7' fragments, respectively, were determined by PDMS. The 7 fragment arises from tryptic peptide mapping of rhGH.
hGH in a concentration of 1 mg/ml was dialysed against 50 mM Tris, 2 mM CaCl2, 6 H20, pH 7.8 for 24 hours af 4°C. 10 μl of a trypsin solution prepared by dissolving 1 mg trypsin (Bovine, DPCC treated, T-1005 from Sigma) pr. ml. 1 mM HC1, 2 mM CaCl2.6H20 was added pr mg. hGH. The digestion was performed in 6 hours at 37°C. The digestion product was analysed (25 μl) using RP-HPLC: Column: Nucleosil RP C18, 250x4 mm, 120 A, 7u (Macherey-Nagel, Art. 720042. Temperature: 45°C. Detection : 215 nm. Flow: 1 ml/min. Eluent E: 0.05% (vol/vol) TFA in water, eluent F: 0.05% (vol/vol) TFA in 70% acetonitrile in water. Gradient: 0 to 70% eluent F during 60 minutes. Then the gradient was changed to 100% F during 5 minutes followed by 10 minutes isocratic elution at 100% F. The gradient was changed back to 0% F during 1 minute and the column was equilibrated for 15 minutes before next run.
The 7 fragment of rhGH produced by tryptic cleavage has a calculated mass of 1401 and the Formula I
Ser-Val-Glu-Ser-C
A difference in mass of 32 amu between the 7 and 7' peptides is observed. After reduction using DTT, identical masses are found for both the 7 and the 7 ' peptides corresponding to the the calculated mass for the reduced peptide.
The results are shown in the below Table II,
Table II
PDMS Calculated
7 fragment 1401 1401
7 fragment + DTT 617 + 785 618 + 785
7 ' fragment 1433
7 'f agtment + DTT 617 + 785
The 7' fragment was isolated by collecting the fraction corresponding to the new peak by RP-HPLC of the trypsin digest as discribed above.
A partial Edman Degradation combined with PDMS analysis as well as ESMS was carried out directly on the 7' fragment. Through four steps it was possible to trace the manual degradation by analyzing the truncated peptide. In each step, two amino acid residues were cleaved off (one from each N- terminal) . The difference in mass of 32 amu between the 7 and 7' peptides was not changed during these four cleavages.
MS/MS analysis by ESMS gave a series of ionized sequences related to the N-terminal part of the peptide. The MS/MS was carried out using the molecular ion of the 7' peptide having the mass 717amu and a double charge. The fragmentation of the "upper chain" gave rise to tops at m/z 1320, 1221, and 1094, whereas the fragmentation of the "lower chain" gave rise to tops at m/z 1247, 1118, 1061, and 974. The conclusion is that the first four amino acid residues in each "chain" - as far as the cystein residues - show normal masses.
Thus, the difference in mass of 32 amu between the rhGH and rhGH' seems to be due to the presence of a trisulphide as opposed to the normal disulphide.
Demonstration of the Presence of Extra Sulphur in hGH1
The presence of a trisulphide bridge was demonstrated using lead acetate as described below.
Treatment of rhGH' with cysteine as described below was demonstrated to transform the rhGH' into native rhGH during which the development of hydrogen sulphide was detected.
Filter paper (Whatman glass microfibre filters) was soaked in a 0.1M solution of lead acetate in distilled water, and air dried.
Six test tubes were prepared having the contents as stated in the below Table III.
Tabel III
2 tubes of 10 ml containing: Water
2 tubes of 10 ml containing: Pure hGH'
2 tubes of 10 ml containing: hGH - without peak 7'
The test tubes were divided into two series as stated in the below Table IV.
Tabel IV
Series I Series II Tube Containing Tube Containing
1 Water 4 Water
2 Pure hGH' 5 Pure hGH' hGH 6 hGH
(without peak 7') (without peak 7')
To all tubes of series I was added 2.5 ml of distilled water.
To all tubes of series II was added 2.5 ml of 2.5 mM cysteine in distilled water.
The paper was cut into six pieces (rondels of a diameter of 3.5 cm) and placed at the top of the eight test tubes. The rondels were moistened by adding 3-4 drops of distilled water, and the test tubes were left in a water bath at 40*C for 24 hours.
After 24 hours the paper rondels were examined. No change was seen for the test tubes having had water added.
On the papers on test tubes 4 and 6 having had added cysteine, a very faint brownish colouring was observed.
The paper on test tube No. 5 showed a dense black spot ascribed to the formation of lead sulphide. The black spot appeared after 10 to 15 minutes.
Example 2
Conversion of Hydrophobic Derivative of Human Growth Hormone into Native Human Growth Hormone
Lyophilized rhGH from a sample comprising rhGH1 was treated as follows for converting the hydrophobic derivative of hGH into native hGH:
A: 4IU hGH were dissolved in 2.5 ml of distilled water.
B: 4IU hGH were dissolved in 2.5 ml of distilled water followed by reduction using 100 μl ercaptoethanol for 10 minutes at ambient temperature. Then the resulting mixture was desalted using PD10 (from Pharmacia,
Sephadex G 25) into 20 mM Tris, pH 8.6. The solution
was left for 2h at 4°C and analyzed by hydrophobic interaction chromatography as described in Example 1.
C: 4IU hGH were dissolved in 2.5 ml of 20 mM Tris, pH
8.6. The solution was left for 2h at 4'C and analyzed by hydrophobic interaction chromatography as described in Example 1.
D: 12IU hGH were dissolved in 7.5 ml of the refolding buffer as disclosed in WO 92/03477: 20mM Tris, 2mM EDTA, 2mM Cysteine. The solution was left for 2h at 4°C and analyzed by hydrophobic interaction chromatography as described in Example 1. The sample was then desalted into 2mM His, pH 6.5 and analyzed hydrophobic interaction chromatography as described in Example 1.
The results show that redissolution in the folding buffer (sample D) which is weakly reducing but ensures effective disulphide formation causes transformation of the rhGH1 into native rhGH.
Redissolution in water or Tris, pH 8.5 does not cause conversion (Sample A and C) . If the rhGH' is completely reduced using mercaptoethanol giving a form of hGH identical to the form found in E.Coli cells (but without the presence of hydrogen disulphide in the medium) before homogenization, a correct folding may be obtained in Tris pH 8.5 without the addition of cysteine (sample B) .
As shown above, rhGH' may be transformed into native hGH in the presence of 2mM cysteine. When expressing rhGH as a precursor having an amino terminal extension to be cleaved using DAP1, the cleavage may be in a medium comprising cysteine enhancing the formation of the native product having the correct disulphide bridges.
In this case the conversion and cleavage is suitably carried out in two stages, first at a high pH for converting the hydrophobic derivative whereafter the pH is lowered in order to effect the cleaving of the amino terminal extension.
To 4.5 ml of the eluate from the first purification step in normal purification of rhGH in 20mM Tris pH 7.5 comprising chloride ions, 10 mM citric acid at 4°C was added 0.5 ml 20mM cysteine solution in distilled water.
Samples were drawn after 1, 2, 4, 8, 16, 32 and 64 minutes, desalted using a NAP-5 column (Pharmacia) according to the manufactorer's instructions eluting with 25mM Tris. After elution, the pH was adjusted to 7.5, and the contents of 7' peptide was carried out by hydrophobic interaction chromatography as described in Example 1. After 1 minute the peak corresponding to the 7' protein had been reduced by -75%, and after 4 minutes, the top had disappeared totally. Thus, the 7' protein may be converted quantitatively into the native protein by treatment with 2mM cysteine for 4 minutes at 4'C.
Then the pH was adjusted to 4-4.5 for cleaving off an extension, if present.
Example 3
Conversion of Hydrophobic Derivative of Human Growth Hormone into Native Human Growth Hormone
Folding experiments were carried out with a concentration of 2 mM Cys at different pH (4.3, 6.0, 7.5). As starting material was used hGH containing hGH'. 1 ml starting material (cone. 0.7 mg/ l) was adjusted to the chosen pH and mixed with 1 ml 4 mM EDTA, 4 mM Cys, 40 mM Tris, 20 mM Citric acid. At different intervals samples were withdrawn and immediately
desalted on a NAP-5 column (Pharmacia) against 20 mM Tris, 10 mM Citric acid adjusted to the chosen pH as above. HIC analysis was carried out using the first-mentioned system in Example 1.
The results of the experiments carried out at ambient temperatures were as follows:
The starting material had a content of hGH' of 8%.
At pH 4.3 the contents of hGH' was reduced to 7.7% after 4 minutes and a sample left overnight still had a content of hGH' of 6%.
At pH 6.0 the contents of hGH1 was reduced to 6.0% after 4 minutes and to 1.7% after 64 minutes. After 20 hours no hGH' was detected.
At pH 7.5 the contents of hGH' was reduced very rapidly. After 1 minute to 2.6%, after 2 minutes to 1.6%, and after 4 minutes, no hGH' was detectable.
The results of carrying out the conversion at a temperature of of 4°C and at pH 7.3 were:
After 2 minutes, the contents of hGH' was reduced to 2.5%, after 4 minutes to 1%, and after 8 minutes, no hGH' could be detected.
This shows that the conversion proceeds rapidly and quantitatively at a pH of 7.5 and more slowly and incomplete at lower pH.
The influence of the temperature is of minor importance.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Novo Nordisk A/S
(B) STREET: Novo Alle
(C) CITY: DK-2880 Bagsvaerd (E) COUNTRY: Denmark
(G) TELEPHONE: +45 44448888 (H) TELEFAX: +45 44490555 (I) TELEX: 37173
(ii) TITLE OF INVENTION: A Method of Detecting the Presence of and Converting of a Polypeptide
(iii) NUMBER OF SEQUENCES: 2
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25
(EPO)
(v) CURRENT APPLICATION DATA: APPLICATION NUMBER: (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: DK 0445/93
(B) FILING DATE: 20-APR-1993
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: lie Val Gin Cys Arg 1 5
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2
Ser Val Glu Ser Cys Gly Phe 1 5
Claims (7)
1. A method for converting a hydrophobic derivative of a growth hormone into the native form of the growth hormone, wherein the derivative of growth hormone is treated with a
5 mercapto compound.
2. A method as claimed in claim 1, wherein the mercapto com¬ pound is selected from the group consisting of cysteine and glutathione, 2-mercapto ethanol and dithiothreitol.
3. A method as claimed in claim 2, wherein the mercapto com- 10 pound is cysteine.
4. A method as claimed in any of claims 1-3, wherein the concentration of the mercapto compound is up to 5 mM.
5. A method as claimed in claim 4, wherein the the mercapto compound is cysteine in a concentration of from 1 to 2 mM.
156. A method as claimed in any of claims 1-5, wherein the growth hormone is human growth hormone.
7. A method for detecting the presence of a hydrophobic derivative of a growth hormone comprising an extra sulphur atom as compared to the native growth hormone wherein the 20 growth hormone is subjected to a hydrophobic interaction chromatography and eluting the column with a salt gradient and detecting the presence of the hydrophobic derivative.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK0445/93 | 1993-04-20 | ||
DK93445A DK44593D0 (en) | 1993-04-20 | 1993-04-20 | PROCEDURE FOR PREPARING A POLYPEPTIDE |
PCT/DK1994/000157 WO1994024157A1 (en) | 1993-04-20 | 1994-04-19 | A method of detecting the presence of and converting of a polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6535594A true AU6535594A (en) | 1994-11-08 |
Family
ID=8093625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU65355/94A Abandoned AU6535594A (en) | 1993-04-20 | 1994-04-19 | A method of detecting the presence of and converting of a polypeptide |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0695310A1 (en) |
JP (1) | JPH08508735A (en) |
KR (1) | KR960701891A (en) |
AU (1) | AU6535594A (en) |
BG (1) | BG100068A (en) |
CA (1) | CA2160663A1 (en) |
CZ (1) | CZ272895A3 (en) |
DK (1) | DK44593D0 (en) |
FI (1) | FI955000A (en) |
HU (1) | HUT73320A (en) |
IL (1) | IL109347A0 (en) |
NO (1) | NO954181L (en) |
PL (1) | PL311198A1 (en) |
WO (1) | WO1994024157A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9802454D0 (en) | 1998-07-08 | 1998-07-08 | Pharmacia & Upjohn Ab | Production of peptides |
ZA200501841B (en) * | 2002-08-28 | 2007-06-27 | Pharmacia Corp | Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof |
US20040048315A1 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof |
US7470779B2 (en) * | 2002-09-20 | 2008-12-30 | Pfizer Inc. | Process for decreasing aggregate levels of pegylated protein |
PL212726B1 (en) * | 2002-09-20 | 2012-11-30 | Pharmacia Corp | Process for decreasing aggregate levels of pegylated protein |
US20090131311A1 (en) | 2004-12-29 | 2009-05-21 | Novo Nordisk Healthcare Ag | Method for Preventing Formation of Trisulfide Derivatives of Polypeptides |
WO2011041721A1 (en) | 2009-10-02 | 2011-04-07 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
WO2012158551A1 (en) | 2011-05-13 | 2012-11-22 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4985544A (en) * | 1987-08-04 | 1991-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for renaturing fish growth hormone |
US5079230A (en) * | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
DE69129747T2 (en) * | 1990-09-05 | 1998-11-12 | Southern Cross Biotech Pty Ltd | BRINGING PROTEINS IN SOLUTION IN ACTIVE FORM |
US5151501A (en) * | 1991-12-20 | 1992-09-29 | American Cyanamid Company | Method for solubilization and naturation of somatotropins utilizing sulfolane |
-
1993
- 1993-04-20 DK DK93445A patent/DK44593D0/en not_active Application Discontinuation
-
1994
- 1994-04-19 CZ CZ952728A patent/CZ272895A3/en unknown
- 1994-04-19 PL PL94311198A patent/PL311198A1/en unknown
- 1994-04-19 KR KR1019950704477A patent/KR960701891A/en not_active Application Discontinuation
- 1994-04-19 WO PCT/DK1994/000157 patent/WO1994024157A1/en not_active Application Discontinuation
- 1994-04-19 AU AU65355/94A patent/AU6535594A/en not_active Abandoned
- 1994-04-19 HU HU9503020A patent/HUT73320A/en unknown
- 1994-04-19 IL IL10934794A patent/IL109347A0/en unknown
- 1994-04-19 EP EP94913048A patent/EP0695310A1/en not_active Withdrawn
- 1994-04-19 CA CA002160663A patent/CA2160663A1/en not_active Abandoned
- 1994-04-19 JP JP6522643A patent/JPH08508735A/en active Pending
-
1995
- 1995-10-17 BG BG100068A patent/BG100068A/en unknown
- 1995-10-19 NO NO954181A patent/NO954181L/en unknown
- 1995-10-19 FI FI955000A patent/FI955000A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO954181D0 (en) | 1995-10-19 |
FI955000A0 (en) | 1995-10-19 |
HU9503020D0 (en) | 1995-12-28 |
CA2160663A1 (en) | 1994-10-27 |
DK44593D0 (en) | 1993-04-20 |
CZ272895A3 (en) | 1996-03-13 |
JPH08508735A (en) | 1996-09-17 |
PL311198A1 (en) | 1996-02-05 |
IL109347A0 (en) | 1994-07-31 |
KR960701891A (en) | 1996-03-28 |
FI955000A (en) | 1995-10-19 |
NO954181L (en) | 1995-10-19 |
EP0695310A1 (en) | 1996-02-07 |
HUT73320A (en) | 1996-07-29 |
WO1994024157A1 (en) | 1994-10-27 |
BG100068A (en) | 1996-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Burgus et al. | Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone | |
Nilsson | Structure of the vasoactive intestinal octacosapeptide from chicken intestine. The amino acid sequence | |
Schellenberger et al. | The precursor to B-type natriuretic peptide is an O-linked glycoprotein | |
RUBIN et al. | Isolation and partial sequence analysis of rat basic somatomedin | |
Nilsson et al. | Integrated production of human insulin and its C-peptide | |
Jackson et al. | A comparison of the major apolipoprotein from pig and human high density lipoproteins | |
Foltmann et al. | Human progastricsin: analysis of intermediates during activation into gastricsin and determination of the amino acid sequence of the propart | |
Maghuin‐Rogister et al. | Luteinizing Hormone: The Primary Structures of the β‐Subunit from Bovine and Porcine Species | |
Wallis | The primary structure of bovine prolactin | |
CZ171492A3 (en) | Polypeptide, process of its preparation, pharmaceutical composition containing thereof and its use as an intermediate for insulin preparation | |
Sairam et al. | Human pituitary lutropin: Isolation, properties, and the complete amino acid sequence of the β-subunit | |
Fellows Jr et al. | Structural Studies on Bovine Growth Hormone: I. Isolation and characterization of cyanogen bromide fragments | |
Nilsson | Isolation, amino acid composition and terminal amino acid residues of the vasoactive octacosapeptide from chicken intestine. Partial purification of chicken secretin | |
Nyberg et al. | Human pituitary prolactin. Isolation and characterization of three isohormones with different bioassay and radioimmunoassay activities | |
Mor et al. | Identification of a D-alanine-containing polypeptide precursor for the peptide opioid, dermorphin. | |
Gowan et al. | On the primary and tertiary structure of relaxin from the sand tiger shark (Odontaspis taurus) | |
AU6535594A (en) | A method of detecting the presence of and converting of a polypeptide | |
Soedjanaatmadja et al. | Demonstration by mass spectrometry that pseudo-hevein and hevein have ragged C-terminal sequences | |
IL91457A (en) | Variant somatotropins and compositions containing them for growth enhancement and for increasing milk production in mammals | |
WO1996002570A1 (en) | A method of converting a hydrophobic derivative of a polypeptide into the native form | |
Fujiki et al. | Studies on the disulfide bonds in human pituitary follicle-stimulating hormone | |
Plevrakis et al. | Proocytocin neurophysin convertase from bovine neurohypophysis and corpus luteum secretory granules: complete purification, structure-function relationships, and competitive inhibitor | |
Muranova et al. | The primary structure of ribosomal protein L3 from Escherichia coli 70 S ribosomes | |
Arámburo et al. | Partial biochemical and biological characterization of purified chicken growth hormone (cGH). Isolation of cGH charge variants and evidence that cGH is phosphorylated | |
Castellanos-Serra et al. | Expression and folding of an interleukin‐2‐proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C‐peptide and the N‐terminal fused sequence |